CIAM
MBRX icon

Caitong International Asset Management’s Moleculin Biotech MBRX Stock Holding History

Caitong International Asset Management’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2
Closed -$5 – 3272
2026
Q1 		$5 Buy
+2
New +$7 ﹤0.01% 2285

Other funds holding MBRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Caitong International Asset Management's MBRX Position: Q2 2026 in Review

Caitong International Asset Management sold out of Moleculin Biotech (MBRX) in Q2 2026, closing a stake of 2 shares — an estimated $5 sold.

Caitong International Asset Management first reported a position in MBRX in Q1 2026 and held it in 1 quarter. The position peaked at $5 in Q1 2026. 18 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.

  • Caitong International Asset Management reported no remaining Moleculin Biotech position as of Q2 2026 after selling out during the quarter.
  • Caitong International Asset Management sold 2 Moleculin Biotech shares in Q2 2026, an estimated $5.
  • Caitong International Asset Management first reported a position in Moleculin Biotech in Q1 2026 and held it in 1 quarter.
  • Caitong International Asset Management's Moleculin Biotech position peaked at $5 in Q1 2026.
  • 18 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.